Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cadonilimab vs Chemo+PD-1 in Resectable NSCLC
NCT06946836Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Apr 2025
- Primary completion
- May 2031
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06946836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946836.